Combination of Axitinib and Nivolumab Safe for Patients with Metastatic Renal Cell Carcinoma, Efficacy Testing Ongoing
PHILADELPHIA (May 23, 2019) — A new combination of established kidney cancer drugs has demonstrated safety and encouraging efficacy in patients with metastatic renal cell carcinoma (mRCC), according to a new clinical trial lead by Matthew Zibelman, MD, on the combination of Axitinib and the PD-1 inhibitor Nivolumab.